IL100330A - Salt 3- [2- (dimethylamino) ethyl] - N-methyl-H1-methanesulfonamino sulfate) 2: 1, process for its preparation and a pharmaceutical preparation containing it - Google Patents

Salt 3- [2- (dimethylamino) ethyl] - N-methyl-H1-methanesulfonamino sulfate) 2: 1, process for its preparation and a pharmaceutical preparation containing it

Info

Publication number
IL100330A
IL100330A IL10033091A IL10033091A IL100330A IL 100330 A IL100330 A IL 100330A IL 10033091 A IL10033091 A IL 10033091A IL 10033091 A IL10033091 A IL 10033091A IL 100330 A IL100330 A IL 100330A
Authority
IL
Israel
Prior art keywords
indole
ethyl
methyl
pharmaceutical composition
salt
Prior art date
Application number
IL10033091A
Other languages
English (en)
Hebrew (he)
Other versions
IL100330A0 (en
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL100330A0 publication Critical patent/IL100330A0/xx
Publication of IL100330A publication Critical patent/IL100330A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
IL10033091A 1990-12-12 1991-12-11 Salt 3- [2- (dimethylamino) ethyl] - N-methyl-H1-methanesulfonamino sulfate) 2: 1, process for its preparation and a pharmaceutical preparation containing it IL100330A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (2)

Publication Number Publication Date
IL100330A0 IL100330A0 (en) 1992-09-06
IL100330A true IL100330A (en) 1996-06-18

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10033091A IL100330A (en) 1990-12-12 1991-12-11 Salt 3- [2- (dimethylamino) ethyl] - N-methyl-H1-methanesulfonamino sulfate) 2: 1, process for its preparation and a pharmaceutical preparation containing it

Country Status (36)

Country Link
US (2) US5554639A (de)
EP (1) EP0490689B1 (de)
JP (1) JP2994037B2 (de)
KR (1) KR100211479B1 (de)
CN (2) CN1030890C (de)
AP (1) AP230A (de)
AT (1) ATE119881T1 (de)
AU (1) AU650706B2 (de)
BE (1) BE1005085A3 (de)
CA (1) CA2098302C (de)
CH (1) CH684192A5 (de)
CY (1) CY2005A (de)
CZ (1) CZ281931B6 (de)
DE (1) DE69108200T2 (de)
DK (1) DK0490689T3 (de)
EG (1) EG20219A (de)
ES (1) ES2069836T3 (de)
FR (1) FR2670487B1 (de)
GB (2) GB9026998D0 (de)
GR (1) GR3015430T3 (de)
HK (1) HK82697A (de)
HU (1) HU211937A9 (de)
IE (1) IE62894B1 (de)
IL (1) IL100330A (de)
IS (1) IS1706B (de)
IT (1) IT1252868B (de)
MX (1) MX9102501A (de)
MY (1) MY109265A (de)
NL (1) NL9102071A (de)
NZ (1) NZ240942A (de)
PT (1) PT99757B (de)
RU (1) RU2108328C1 (de)
TW (2) TW300886B (de)
WO (1) WO1992010477A1 (de)
YU (1) YU48926B (de)
ZA (1) ZA919750B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG50406A1 (en) * 1992-06-05 1998-07-20 Merck Sharp & Dohme The sulphate salt of a sustituted triazole pharmaceutical compositions thereof and their use in therapy
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
SI1575566T1 (sl) * 2002-12-26 2012-08-31 Pozen Inc Veäśplastna dozirna oblika vsebujoäśa naproksen in triptane
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
EP2026790A2 (de) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US8580791B2 (en) 2008-05-27 2013-11-12 Biota Scientific Management Pty Ltd Antiviral 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole bis-dihydrogen-phosphate salts
CA2765866C (en) * 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8592424B2 (en) * 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3311667A1 (de) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
AU2010299607B2 (en) 2009-09-25 2016-07-28 Tonix Medicines, Inc. Formulations comprising triptan compounds
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10494405B2 (en) 2015-05-15 2019-12-03 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
MX2020004566A (es) 2017-11-07 2020-08-13 Univ Michigan Regents Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2021173936A1 (en) * 2020-02-27 2021-09-02 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
AP230A (en) 1993-01-27
CH684192A5 (fr) 1994-07-29
EG20219A (en) 1997-11-30
GB2251614A (en) 1992-07-15
ATE119881T1 (de) 1995-04-15
ITRM910922A1 (it) 1993-06-11
CA2098302A1 (en) 1992-06-13
JPH06503560A (ja) 1994-04-21
CA2098302C (en) 2001-10-16
EP0490689B1 (de) 1995-03-15
HU211937A9 (en) 1996-01-29
GB9126297D0 (en) 1992-02-12
YU191491A (sh) 1994-04-05
PT99757B (pt) 1999-05-31
GR3015430T3 (en) 1995-06-30
FR2670487B1 (fr) 1993-08-20
MX9102501A (es) 1992-09-01
CN1050831C (zh) 2000-03-29
TW300886B (de) 1997-03-21
CN1128259A (zh) 1996-08-07
PT99757A (pt) 1992-12-31
ES2069836T3 (es) 1995-05-16
YU48926B (sh) 2002-12-10
NZ240942A (en) 1994-03-25
IE62894B1 (en) 1995-03-08
AU650706B2 (en) 1994-06-30
DE69108200T2 (de) 1995-07-20
CZ281931B6 (cs) 1997-04-16
AP9100339A0 (en) 1992-01-31
US5705520A (en) 1998-01-06
IT1252868B (it) 1995-06-28
IS1706B (is) 1998-12-10
CY2005A (en) 1997-12-05
GB2251614B (en) 1994-12-14
US5554639A (en) 1996-09-10
MY109265A (en) 1996-12-31
GB9026998D0 (en) 1991-01-30
CN1063099A (zh) 1992-07-29
ZA919750B (en) 1992-10-28
IL100330A0 (en) 1992-09-06
HK82697A (en) 1997-06-27
NL9102071A (nl) 1992-07-01
IE914317A1 (en) 1992-06-17
TW205035B (de) 1993-05-01
DE69108200D1 (de) 1995-04-20
JP2994037B2 (ja) 1999-12-27
EP0490689A1 (de) 1992-06-17
BE1005085A3 (fr) 1993-04-13
ITRM910922A0 (it) 1991-12-11
CN1030890C (zh) 1996-02-07
DK0490689T3 (da) 1995-05-22
WO1992010477A1 (en) 1992-06-25
CZ114093A3 (en) 1994-02-16
FR2670487A1 (fr) 1992-06-19
KR100211479B1 (ko) 1999-08-02
RU2108328C1 (ru) 1998-04-10
AU9072091A (en) 1992-07-08
IS3790A7 (is) 1992-06-13

Similar Documents

Publication Publication Date Title
AU650706B2 (en) Medicaments
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
NZ208127A (en) Pharmaceutical compositions containing ranitidine
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
US7576133B2 (en) Methods and compositions for nasal administration of modafinil
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
KR20050109077A (ko) 5-메틸-2-2'-(클로로-6'-플루오로아닐리노)페닐아세트산을포함하는 제약 조성물
JPH07215877A (ja) 点鼻液剤
EP0840733B1 (de) Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
RU2710372C2 (ru) Композиции, содержащие триптановые соединения
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXTP Application for extension order is pending
PEL Intention of commissioner to extend period of protection
MM9K Patent not in force due to non-payment of renewal fees